Reshma Kewalramani is Chief Executive Officer and President of Vertex Pharmaceuticals Inc (VRTX). The company reported total compensation of $21,144,261 for fiscal year 2025.
| Salary | $1,600,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $15,002,270 |
| Option awards | $0 |
| Non-equity incentive plan | $4,118,640 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $423,351 |
| Total | $21,144,261 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Vertex Pharmaceuticals Inc filed April 2, 2026, accession 0000875320-26-000153.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer and President | $1,600,000 | $0 | $15,002,270 | $0 | $4,118,640 | $0 | $423,351 | $21,144,261 |
| FY2024 | Chief Executive Officer and President | $1,541,154 | $0 | $15,002,202 | $0 | $4,941,600 | $0 | $53,712 | $21,538,668 |
| FY2023 | Chief Executive Officer and President | $1,500,000 | — | $15,001,894 | — | $4,050,000 | — | $42,547 | $20,594,441 |
| FY2022 | Chief Executive Officer and President | $1,396,154 | — | $10,640,784 | — | $3,784,500 | — | $43,059 | $15,864,497 |
| FY2021 | Chief Executive Officer and President | $1,221,923 | — | $10,924,599 | — | $3,016,570 | — | $35,764 | $15,198,856 |
Totals as disclosed in each year's own compensation disclosure for Vertex Pharmaceuticals Inc.
| Peer-group chief executive median | $24,169,562 |
|---|---|
| Difference from that median | $-3,025,301 |
| Percentile within the disclosed peer group | 30th |
| Peers with a disclosed figure | 10 |
Medians and percentiles are computed across the peer group Vertex Pharmaceuticals Inc discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Reshma Kewalramani this page | Chief Executive Officer and President | $21,144,261 |
| Stuart Arbuckle | Former Executive Vice President, Chief Operating Officer | $9,996,347 |
| Charles Wagner | Executive Vice President, Chief Operating and Financial Officer | $8,241,809 |
| Nia Tatsis | Executive Vice President, Chief Regulatory and Quality Officer | $6,974,920 |
| Amit Sachdev | Executive Vice President, Chief Patient and External Affairs Officer | $6,777,243 |
| Carmen Bozic | Executive Vice President, Chief Medical Officer | $6,646,321 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Vertex Pharmaceuticals Inc compensation brief.
Reshma Kewalramani's compensation sits inside Vertex Pharmaceuticals Inc's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.